MPN Education Foundation


Donate Now

Join the MPN-NET Online Support

The mission of MPN-NET, and Online Forum, is to bring information, education and support to our members

Join Now

2021 MPN Heroes Recognition Program

Nominations will open soon for the 2021 MPN Heroes® Recognition Program!

Nominate Now

Myeloproliferative Neoplasms

Myeloproliferative neoplasms (MPN) are relatively rare chronic hematologic malignancies that include the classic Myeloproliferative Neoplasm Disorders:

Philadelphia chromosome-negative
Essential Thrombocythemia (ET)
Myelofibrosis (MF)
Polycythemia Vera (PV)

Philadelphia chromosome-positive
Chronic Myelogenous Leukemia (CML)

There are atypical Myeloproliferative Neoplasm Disorders which include molecularly defined PDGFRA-rearranged eosinophilic/mast cell disorders; PDGFRB-rearranged eosinophilic disorders; systemic mastocytosis associated with c-kit mutation; 8p11 Myeloproliferative syndrome; and juvenile myelomonocytic leukemia with recurrent mutations of RAS. MPN also includes the clinicopathologically assigned variants: chronic neutrophilic leukemia; chronic eosinophilic leukemia; hypereosinophillic syndrome, chronic basophilic leukemia, chronic monomyelomonocytic leukemia, systemic mastocytosis; and unclassified myeloproliferative disorder. Chronic myeloid disorders also include myelodysplastic syndrome.

If you or a loved one have been diagnosed with one of these rare disorders,

Click Here to join MPN-NET Support.


Scientific Advisory Board:
John Camoriano, MD, Mayo Clinic, Scottsdale, Arizona
Joachim Deeg, MD, Fred Hutchinson Cancer Research Center, Seattle, Washington
Claire Harrison, MD, Guy’s and St. Thomas’ Hospital, London, UK
Ruben Mesa, MD, UT Health San Antonio TX
Ayalew Tefferi, MD, Mayo Clinic, Rochester, Minnesota
Srdan Verstovsek, MD, MD Anderson Cancer Center, Houston, Texas